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We have reported that infection of fetal or neonatal rhesus macaques with attenuated SIVmac1A11 results in transient
viremia, anti-SIV antibody responses, weak or absent cytotoxic T-lymphocyte responses, and no clinical disease. In light of
these results, we hypothesized that congenital infection with SIVmac1A11 produced immune tolerance to SIV. To test this
hypothesis, at approximately 1 year of age, five rhesus macaques infected with SIVmac1A11 as fetuses (n  3) or newborns
(n  2) and five naive juvenile rhesus macaques were challenged orally with pathogenic SIVmac251. The five naive animals
became persistently viremic after oral SIVmac251 inoculation. In contrast, one of three monkeys inoculated with SIVmac1A11
in utero and one of two animals inoculated with SIVmac1A11 at birth were virus culture negative. Virus was isolated from
PBMC of the other animals infected with SIVmac1A11 in utero or at birth. However, one animal had a substantially lower
viral load than the control animals. These results suggest that SIV-specific immunity rather than tolerance results from
congenital infection with attenuated SIVmac and that this immunity is sufficient to provide some protection from pathogenic
virus challenge. These results also demonstrate that SIV can be transmitted orally in 6- to 17-month-old rhesus monkeys.
q 1996 Academic Press, Inc.
We have previously shown that simian immunodefi- the viral load and immunological measures after oral
SIVmac251 challenge of these animals.ciency virus (SIV) infection of rhesus macaque fetuses
and neonates is a useful model for the study of human The monkeys were challenged orally because oral
transmission by breast feeding is a recognized route ofpediatric AIDS pathogenesis (1–3). Direct inoculation of
rhesus monkey fetuses or newborns with SIVmac251 re- HIV transmission in pediatric populations (4–7). Five ju-
venile rhesus macaques previously infected with SIV-sulted in persistently high viremia, immunosuppression,
and rapidly progressive simian AIDS. In contrast, infec- mac1A11 either in utero on Gestational Day 65 (early
tion of fetuses or neonates with the attenuated molecular second trimester, n  3, Ref. 8) or at birth (n  2, Ref. 1)
clone, SIVmac1A11, resulted in transient viremia, anti- were orally inoculated with SIVmac251 at 12–17 months
SIV antibody responses, weak or absent cytotoxic T-lym- of age (Table 1). Five naive animals were orally inocu-
phocyte (CTL) responses, and no disease. The purpose lated at 6–17 months of age (Table 1); two of these
of the present study was to test the hypothesis that mon- monkeys had previously been exposed to SIV but were
keys infected congenitally with an attenuated lentivirus not infected. A cell-free stock of SIVmac251 grown in
develop immunological tolerance to pathogenic SIV. To rhesus peripheral blood mononuclear cells (PBMC) with
test this hypothesis, monkeys that had been previously a titer of 105 TCID50 per milliliter was used for inoculation
infected with attenuated SIVmac1A11 as fetuses or neo- (9). For oral inoculation, 1 ml of the viral inoculum was
nates were challenged orally with pathogenic SIVmac251 slowly dispensed by syringe into the oral cavity and the
at approximately 1 year after birth. We have previously animals were observed closely to confirm that the viral
reported the virological, immunological, and clinical pa- inoculum was swallowed.
rameters of these animals after they were infected with Cell-associated and cell-free viremia were quantified
SIVmac1A11 as fetuses or at birth (1–3). Here we report by limiting dilution culture of PBMC and plasma with
CEMx174 cells as previously described (10). Plasma anti-
bodies to SIV were detected using a whole virus ELISA
1 To whom correspondence and reprint requests should be ad-
as previously described (2). To detect anti-SIV CTL activ-dressed at California Regional Primate Research Center, University of
ity, PBMC from the animals were stimulated with SIVCalifornia, Davis, Davis, CA 95616-8542. Fax: (916) 752-2880. E-mail:
mbmcchesney@ucdavis.edu. antigen followed by a conventional chromium release
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TABLE 1
Viral Load and Immune Response before and after Pathogenic SIVmac251 Challenge
4 Weeks before challenge 12 Weeks after challenge
Age (months)
at time of Anti-SIV Anti-SIV Anti-SIV Anti-SIV
Group Monkey No. challenge Virus loada antibody titerb CTLc Virus load antibody titer CTL
Fetal
SIVmac1A11
inoculation 27700 14 0.1 100 10% 316 62,500 21%
27812 13 0.1 12,500 10% 0.1 100 12%
27820 12 0.1 100 10% 0.1 2,500 40%
Neonatal
SIVmac1A11
inoculation 27315 17 0.1 100 10% 215 62,500 37%
27403 16 0.1 12,500 10% 0.1 500 10%
Naive 27372 15 0.1 100 nd 1,000 2,500 nd
27446 13 0.1 100 nd 100 12,500 10%
27815 6 0.1 100 nd 2.2 62,500 36%
28373 6 0.1 100 10% 1,000 62,500 nd
28468 16 0.1 100 10% 21,530 62,500 nd
Note. nd denotes not done.
a TCID 50% per million PBMC or LNMC as explained in the text.
b Reciprocal of anti-SIV IgG antibody ELISA titers.
c Lysis of vvgag or vv env-infected target cells at an effector to target ratio of 100:1.
assay as previously described (11). Targets cells were 27820, had 10- to 1000-fold lower virus levels than the
control animals (Fig. 1). The other two animals had viralautologous B cells transformed with Herpes papio virus
(provided by M. Sharp, Southwest Foundation for Bio- loads that were similar to the naive controls.
All five naive control monkeys made primary anti-SIVmedical Research, San Antonio, TX) and infected with
wild-type vaccinia (vvWR) or recombinant vaccinia vi- antibody responses by 4 weeks after SIVmac251 chal-
lenge (Fig. 2). The animals that were infected with SIV-ruses expressing SIVmac239 p55gag (vvgag) or gp160
envelope (vvenv) genes (donated by L. Giavedoni and T. mac1A11 in utero or at birth, and that became viremic
after SIVmac251 challenge, mounted secondary anti-SIVYilma, University of California, Davis). SIVmac239 and
SIVmac1A11 are molecular clones derived from the bio- antibody responses by 4 weeks postchallenge (Fig. 2).
However, the antibody titers of the two animals that werelogic isolate, SIVmac251, and they have greater than 98%
nucleotide sequence homology (12). SIV-specific CTL ly- aviremic after challenge declined from prechallenge lev-
els (Table 1 and Fig. 2). All three animals inoculatedsis was considered positive if greater than 10% specific
lysis and greater than twofold the lysis of the vvWR target. with SIVmac1A11 as fetuses made anti-SIV-specific CTL
responses after challenge (Table 1). These three animalsAll five naive animals became viremic after oral SIV-
mac251 challenge; four of these animals had persistently had no detectable CTL immediately prior to challenge.
One of two animals infected with SIVmac1A11 as neo-high viremia for the 12 weeks of observation (Table 1,
Fig. 1). At the time of challenge, the five rhesus monkeys nates became viremic after challenge and made an anti-
SIV-specific CTL response (Table 1).previously infected with SIVmac1A11 were virus isolation
negative in lymph node mononuclear cells (11) and Mammalian fetuses exposed to a variety of antigens
can develop a condition of immunologic nonrespon-PBMC (Table 1). After pathogenic SIVmac251 challenge,
monkey 27812, infected with SIVmac1A11 in utero, and siveness or tolerance to antigens (13, 14). Immune toler-
ance is not an absolute phenomenon. A condition termedmonkey 27403, infected with SIVmac1A11 at birth, were
virus culture negative during the 12-week observation ‘‘split tolerance’’ has been described in which an animal
is capable of mounting an antibody response to the anti-period (Table 1 and Fig. 1). Twelve weeks after the first
challenge, these two animals were rechallenged orally gen but is unable to make a cell-mediated immune re-
sponse (15). In mice, fetal or neonatal infection withwith twice the dose of SIVmac251 used for the initial
challenge. They remained virus isolation negative for 3 lymphocytic choriomeningitis virus (LCMV) results in split
tolerance (16). These animals make anti-LCMV antibod-months (data not shown). Virus was isolated from PBMC
of the other three animals infected with SIVmac1A11 in ies but do not make LCMV-specific CTL (17). It is possible
that inoculation of fetal rhesus macaques with SIV-utero or at birth. However, one of these animals, monkey
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FIG. 1. Viral load in PBMC from rhesus macaques infected with pathogenic SIVmac251. The shaded area represents the range of viral levels for
five naive animals, the dashed lines represent animals infected with SIVmac1A11 in utero (n, monkey 278812; ,, monkey 27820; and s, monkey
27700), and solid lines represent animals infected with SIVmac1A11 at birth (h, monkey 27403; and *, monkey 27315).
mac1A11 could have induced tolerance to SIV. If the exposed to viral antigen during a developmental stage
in which tolerance could be induced (19, 20).animals were subsequently infected with pathogenic SIV,
the condition of tolerance would be expected to pro- Fetal or neonatal infection with virulence-attenuated
SIVmac1A11 protected some rhesus macaques againstfoundly alter the course of the infection. Prior to challenge
with SIVmac251, the rhesus macaques inoculated with oral challenge with pathogenic SIVmac251. In fact, two
animals were completely protected from two widelySIVmac1A11 as fetuses made anti-SIV specific antibod-
ies but did not have detectable anti-SIV CTL. Although spaced oral challenge-exposures to pathogenic SIV.
Three of the monkeys that were infected as fetuses orthis is consistent with the condition of split tolerance,
these animals developed SIV-specific CTL responses neonates with SIVmac1A11 became viremic after oral
challenge with SIVmac251, but one of these animals hadafter the SIVmac251 challenge. This indicates that in
utero exposure to SIVmac1A11 did not induce tolerance 10- to 1000-fold lower cell associated virus load than
the naive control animals (Fig. 1). The mechanism(s) ofin these rhesus macaques. After inoculation of fetal and
neonatal rhesus macaques, SIVmac1A11 can be isolated protection in these animals is not obvious. At the time
of challenge, all but one of the animals infected as fe-from PBMC only in the acute stages of infection (1, 8).
These animals may not have been exposed to sufficient tuses or neonates with SIVmac1A11 had anti-SIV serum
antibodies, but none had detectable anti-SIV CTL inviral antigen over time to induce or maintain tolerance,
as has been reported in the LCMV-mouse model (18). PBMC. In other viral infections, both virus-specific anti-
bodies and anti-viral CTL have been identified as im-An alternative explanation is that the animals were not
FIG. 2. Anti-SIV antibody responses after challenge with pathogenic SIVmac251. The responses of two of the naive monkeys are shown in A,
and the responses of the five monkeys previously infected with SIVmac1A11 are shown in B. In B, the lines and symbols are the same as those
in Fig. 1.
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